<img height="1" width="1" style="display:none" src="https://www.facebook.com/tr?id=588502574185296&amp;ev=PageView&amp;noscript=1">

In this article

    The ‘Fat-Loss Shot Stack’ That Could Replace Ozempic®: Retatrutide + Cagrilintide Explained

    Dr. Jean-Paul Leva Dr. Jean-Paul Leva
    Oct 26, 2025 5 min read

    If you thought Ozempic® was the endgame for medical weight loss, think again.
    Pharma giants are now developing a dual-hormone stack so potent it’s being called the “Fat-Loss Shot Stack.”

    Patients often ask about the newest generation of GLP-based therapies, and two names keep coming up: Retatrutide weight loss and Cagrilintide fat loss.

    This article breaks down:

    • What each drug does

    • Why stacking them could accelerate results

    • How they compare to Ozempic vs Retatrutide

    • What’s next for this next-generation treatment

     

    Comparative Weight Loss from Leading GLP-Based Therapies

    Key Takeaways

    • Retatrutide is a triple-hormone agonist (GLP-1/GIP/glucagon) showing notable fat-loss results in clinical trials.

    • Cagrilintide is an amylin analog that enhances satiety and may complement GLP drugs.

    • Combined, they could form a next-gen weight loss injections stack,  targeting appetite, metabolism, and energy expenditure.

    • Researchers hope this duo may surpass Ozempic® (semaglutide) in both speed and magnitude of results.

    • Both drugs are still under investigation; safety, dosing, and FDA approval are pending.

    What Is Retatrutide?

    Retatrutide (LY3437943) is Eli Lilly’s experimental triple-agonist drug that activates:

    1. GLP-1 (Glucagon-like peptide-1) – reduces appetite and slows digestion

    2. GIP (Glucose-dependent insulinotropic peptide) – enhances insulin sensitivity

    3. Glucagon receptor – increases fat metabolism and energy expenditure

    In phase-2 trials, Retatrutide produced substantial body-weight reduction, which is why it has drawn so much attention from researchers and patients alike.

    What Is Cagrilintide?

    Cagrilintide (NN00739) is a synthetic analog of amylin, a hormone released with insulin that promotes satiety and slows gastric emptying.

    It works differently from GLP-1 drugs, acting as a complementary mechanism:

    • Increases fullness signals to the brain

    • Decreases cravings and meal frequency

    • Helps sustain steady blood-sugar control

    Cagrilintide has been studied both as a solo treatment and in combination with semaglutide, showing synergistic weight-loss effects beyond either alone.

    The Science Behind the “Fat-Loss Shot Stack”

    Researchers are now exploring the potential synergy between Retatrutide + Cagrilintide, combining GLP-1/GIP/glucagon activation with amylin signaling for multi-pathway fat loss.

    This stack could theoretically:

    • Suppress appetite more effectively than semaglutide

    • Enhance calorie burn via glucagon activation

    • Preserve lean mass while reducing fat mass

    • Stabilize hunger hormones for long-term maintenance

    This combination is still being explored, and researchers will need larger, longer trials before anyone knows whether it represents a shift in obesity medicine.

    How Does It Compare to Ozempic®?

    Ozempic® (semaglutide) works on a single pathway: it activates the GLP-1 receptor, which reduces appetite and slows digestion. Retatrutide adds GIP and glucagon activity on top of GLP-1, and Cagrilintide adds amylin signaling, which acts on fullness through a separate route. In theory, hitting several pathways at once could produce stronger appetite control and a larger effect on metabolism than a single-pathway drug.

    There are important differences beyond mechanism. Semaglutide is already FDA-approved and has years of real-world use behind it, so its side effects and dosing are well understood. Retatrutide and Cagrilintide are still investigational, which means their long-term safety, ideal doses, and how they behave when combined are not yet settled. More pathways can also mean more potential side effects, such as nausea, constipation, and fatigue, so any future combination will need careful medical supervision.

    For now, the comparison is mostly about potential rather than proven results. Anyone interested in medical weight loss today should talk with a qualified provider about approved options and a plan that fits their health history.

    Benefits & Considerations

    Potential Benefits:

    • Greater total fat loss

    • Reduced hunger and cravings

    • Possible metabolic improvements beyond semaglutide

    • May help maintain results long-term

    Considerations:

    • Not yet FDA-approved

    • Side effects may overlap (nausea, constipation, fatigue)

    • Long-term safety data still limited

    Why This Matters for the Future of Weight Management

    The combination of Retatrutide + Cagrilintide represents the next evolution of metabolic pharmacology, one that treats obesity like the complex, multi-hormonal disease it is.

    For readers in Queens, Elmhurst, and Forest Hills who are following these developments, the practical step today is a consultation to review currently approved options, realistic goals, and how a supervised weight-loss plan could work for them.

    Frequently Asked Questions

    Not yet. As of 2025, it’s still in phase-3 clinical trials by Eli Lilly.

     

    Cagrilintide is still investigational in the U.S. but may be available through clinical studies.

     

    Semaglutide targets only GLP-1, while Retatrutide + Cagrilintide target four hormonal pathways for more comprehensive fat-loss potential.

    Tolerance is still being evaluated, and official dosing and long-term safety guidelines are still under evaluation.

    It could become a successor class, but Ozempic® remains a widely used, approved option until new drugs are fully approved.

    About Leva Medical

    Leva Medical has offices in Queens (94-06 59th Ave, Suite E9, Elmhurst, NY 11373) and in Northport, Long Island (320 Laurel Rd, Northport, NY 11768).

    Call (718) 699-9737 to book a consultation with our board-certified doctors.

    Dr. Jean-Paul Leva

    Dr. Jean-Paul Leva

    Dr. Jean-Paul Leva, FACS is board certified in cosmetic and general surgery. Dr. Jean-Paul Leva, FACS obtained his Doctor of Osteopathic Medicine degree from ...

    Take the First Step Toward Your Transformation

    Personalized care from board-certified cosmetic surgeons in New York.

    Book Your Consultation or call 929-531-7078

    © 2025 Leva Medical. All rights reserved.

    Disclaimer: Individual results may vary. Patient testimonials and before-and-after images are provided for illustrative purposes only and do not constitute a guarantee of any particular outcome or experience.